Amarin Corp Plc\Uk
$5.75B- Market cap
- $5.88B
- Debt
- +$177.39M
- Cash
- −$302.59M
Capital structure 97% equity / 3% debt · EV / Revenue 26.92x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AMRN stock price at discount vs AVTX $13.99 current versus $9.35K implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AVTX's multiple
Implied fair value · at AMRN's multiple
Snapshot Sep 8, 2026, 1:48 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · AVTX FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 26.92x
Capital structure 100% equity / -0% debt · EV / Revenue 16398.00x
AMRN carries the larger enterprise value at $5.75B against $967.48M; AMRN trades on the lower EV / Revenue multiple (26.92x vs 16398.00x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
AVALO THERAPEUTICS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.39x
-0.06x
Net debt / EBITDA
Leverage against operating earnings
3.79x
1.33x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$98.34M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
CytomX Therapeutics, Inc.
AMRN vs CTMX
IDEAYA Biosciences, Inc.
AMRN vs IDYA
Ocugen, Inc.
AMRN vs OCGN
CLOVER HEALTH INVESTMENTS, CORP. /DE
AMRN vs CLOV
Citius Pharmaceuticals, Inc.
AMRN vs CTXR
$177.39M
-$5.17M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.